Sialylated glycosylphosphatidylinositols suppress the production of toxic amyloid-ß oligomers by Nolan, W et al.
  
RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE 
 
This is the author’s accepted manuscript of the following article. The final publication is available 
at the journal website via http://dx.doi.org/10.1042/BCJ20170239.  
The full details of the published version of the article are as follows: 
 
TITLE: Sialylated glycosylphosphatidylinositols suppress the production of toxic amyloid-β 
oligomers 
AUTHORS: William Nolan, Harriet McHale-Owen & Clive Bate 
JOURNAL TITLE: Biochemical Journal 
PUBLICATION DATE: 22 August 2017 
PUBLISHER:  Portland Press 
DOI: 10.1042/BCJ20170239 
 
 1 
Sialylated glycosylphosphatidylinositols suppress the production of toxic amyloid-β oligomers 
William Nolan1, Harriet McHale-Owen1 & Clive Bate1 
 
1 Department of Pathology and Pathogen Biology, Royal Veterinary College, Hawkshead Lane, North 
Mymms, Herts, UK. AL9 7TA.  
Corresponding Author; Dr Clive Bate, Tel: 01707 666550, Fax 01707 661464. E-mail: cbate@rvc.ac.uk 
 
Abstract 
 
The production of amyloid-β (Aβ) is a key factor driving pathogenesis in Alzheimer’s disease (AD). 
Increasing concentrations of soluble Aβ oligomers within the brain lead to synapse degeneration and the 
progressive dementia characteristic of AD. Since Aβ exists in both disease-relevant (toxic) and non-toxic 
forms, the factors that affected the release of toxic Aβ were studied in a cell model. 7PA2 cells expressing 
the human amyloid precursor protein released Aβ oligomers that caused synapse damage when incubated 
with cultured neurons. These Aβ oligomers had similar potency to soluble Aβ oligomers derived from the 
brains of Alzheimer’s patients. Although the conditioned media from 7PA2 cells treated with the cellular 
prion protein (PrPC) contained Aβ it did not cause synapse damage. The loss of toxicity was associated with 
a reduction in Aβ oligomers and an increase in Aβ monomers. The suppression of toxic Aβ release was 
dependent upon the glycosylphosphatidylinositol (GPI) anchor attached to PrPC and treatment of cells with 
specific GPIs alone reduced the production of toxic Aβ. The efficacy of GPIs was structure dependent and 
the presence of sialic acid was critical. The CM from GPI-treated cells protected neurons against Aβ 
oligomer-induced synapse damage; neuroprotection was mediated by Aβ monomers. These studies support 
the hypothesis that the ratio of Aβ monomers to Aβ oligomers is a critical factor that regulates synapse 
damage.  
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Introduction 
 
Alzheimer's disease (AD) is a complex neurological disorder characterized by a progressive dementia. The 
amyloid hypothesis maintains that the pivotal event in AD is the production of amyloid-β (Aβ) peptides 
following the metabolism of the amyloid precursor protein (APP) [1]. Increasing concentrations of Aβ in 
the brain correlate with disease progression [2]. Critically, not all forms of Aβ have equal biological 
significance; toxicity is dependent upon the state of Aβ, whether that is the length of peptide, state of 
aggregation, homogeneity of aggregates or specific Aβ conformations. The key to understanding the 
amyloid hypothesis is the realization that there exist disease-relevant forms of Aβ, while other forms are 
less toxic or biologically inert [3] and may play a role in normal synapse function [4]. Thus, in this study 
we sought to identify factors involved in the production and release of toxic forms of Aβ. The pathogenesis 
of AD is intimately linked with the loss of synapse function [5, 6]. Many studies demonstrated close 
correlations between the loss of synaptic proteins such as synaptophysin, indicative of synapse 
degeneration, and the degree of dementia in AD [7, 8]. In this study the amounts of synaptophysin and 
cysteine string protein (CSP) were measured to quantify synapse density in cultured neurons incubated with 
Aβ. The loss of synaptic proteins from cultured neurons incubated with Aβ provides a useful in vitro model 
in which to investigate AD-related synapse damage.  
 
7PA2 cells (Chinese hamster ovary cells stably transfected with human APP751[9]) release the soluble Aβ 
oligomers that are considered to be key mediators of synapse damage in AD [10, 11]. The properties of 
soluble Aβ released from 7PA2 cells are similar to those derived from the brains of AD patients [12-14]. 
Since the production of Aβ is affected by the presence of the cellular prion protein (PrPC) [15] the 
biochemistry of PrPC-induced suppression of Aβ production in 7PA2 cells was examined. PrPC is linked to 
membranes via a glycosylphosphatidylinositol (GPI) anchor [16] and is rapidly incorporated into living 
cells [17]. Here we show that treatment of 7PA2 cells with PrPC reduced the release of toxic Aβ as measured 
by their ability to cause synapse degeneration in cultured neurons. This effect of PrPC was dependent upon 
the composition of its GPI anchor; the GPI anchor attached to PrPC is unusual in that it contains sialic acid 
[16] and PrPC with a GPI anchor lacking sialic acid (desialylated PrPC) did not alter the release of toxic Aβ. 
Further studies demonstrate that the suppression of toxic Aβ oligomers was achieved with specific 
sialylated GPIs alone. Treatment of 7PA2 cells with either PrPC or sialylated GPIs reduced the release of 
Aβ oligomers but increased the release of Aβ monomers.   
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Methods 
 
Culture of 7PA2 cells – Chinese hamster ovary (CHO) cells stably transfected with a cDNA encoding 
APP751 (7PA2 cells) were maintained as described [9]. For experiments 7PA2 cells were grown in 6 well 
plates until 80% confluent. Culture media was replaced with neurobasal medium containing B27 
components (Invitrogen) ± test compounds and the cells cultured for a further 3 days and the conditioned 
medium (CM) from these cells (7PA2-CM) was collected. Cells were washed 3 times with ice cold PBS 
and homogenised in an extraction buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.2% 
SDS) containing mixed protease inhibitors (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, 
Aprotinin, Leupeptin, Bestatin, Pepstatin A and E-46) and a phosphatase inhibitor cocktail (PP1, PP2A, 
microcystin LR, cantharidin and p-bromotetramisole (Sigma)) at 106 cells/ml. Cellular debris was removed 
by centrifugation (20 minutes as 16000 x g and the supernatant collected.  Both 7PA2-CM and cell extracts 
were centrifuged at 100,000 x g for 4 hours at 40C and passed through a 50 kDa filter (Sartorius). CM from 
CHO cells (CHO-CM) were used as controls. 7PA2-CM containing Aβ monomers were prepared by 
filtration through a 10 kDa filter (Sartorius). To deplete 7PA2-CM of Aβ they were incubated with 1 μg/ml 
mAb 4G8 (reactive with amino acids 17-24 of Aβ) or an isotype control (mock depletions) and incubated 
on rollers for 2 hours. Protein G microbeads were added (10 µl/ml) (Sigma) for 30 minutes and protein G 
bound-antibody-antigen complexes removed by centrifugation (16,000 x g for 5 minutes). For immunoblot 
analysis, 7PA2-CM/monomer or oligomer preparations were concentrated from 2000 to 100 µls using a 3 
kDa filter (Sartorius). 10 µl of sample were mixed with an equal volume of in 0.5% NP-40, 5 mM CHAPS, 
50 mM Tris, pH 7.4 and separated by electrophoresis. Proteins were transferred onto a Hybond-P 
polyvinylidene fluoride membrane by semi-dry blotting and blocked using 10% milk powder. Aβ was 
detected by incubation with mAb 6E10 (Covance), biotinylated anti-mouse IgG, extravidin-peroxidase and 
enhanced chemiluminescence.  
 
Cell survival - To determine cell viability thiazolyl blue tetrazolium bromide was added to cells at a final 
concentration of 50 µM for 3 hours at 37oC. The supernatant was removed, the formazan product solubilized 
in 200 μl of dimethyl sulfoxide, transferred to an immunoassay plate and absorbance read at 595 nm. 
Neuronal survival was calculated with reference to untreated cells (100% survival). 
Isolation of detergent-resistant membranes (DRMs) (lipid rafts)- These membranes were isolated by 
their insolubility in non-ionic detergents as described [18]. Briefly, cells were homogenised in an ice-cold 
buffer containing 1% Triton X-100, 10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 10 mM EDTA and mixed 
protease/phosphatase inhibitors and nuclei and large fragments were removed by centrifugation (300 x g 
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for 5 minutes at 4oC). The post nuclear supernatant was incubated on ice (4oC) for 1 hour and centrifuged 
(16,000 x g for 30 minutes at 4oC). The supernatant was reserved as the detergent soluble membrane (DSM) 
while the insoluble pellet was homogenised in extraction buffer supplemented with protease and 
phosphatase inhibitors (as above) at 106 cells/ml, centrifuged (10 minutes at 16,000 x g) and the soluble 
material was reserved as the DRM fraction.  
Primary neuronal cultures - Cortical neurons were prepared from the brains of mouse embryos (day 15.5) 
after mechanical dissociation and cell sieving as described [19]. Neurons were plated at 2 x 105 cells/well 
in 48 well plates in Hams F12 containing 5% foetal calf serum for 2 hours.  Cultures were shaken (600 
r.p.m for 5 mins) and non-adherent cells removed by 2 washes in PBS. Cells were subsequently grown in 
neurobasal medium containing B27 components (Invitrogen) and nerve growth factor (5 ng/ml) (Sigma) 
for 10 days. Immunohistochemistry showed that greater than 90% of cells were neurofilament positive. 
Neurons were incubated with Aβ preparations or prostaglandin E2 and synapse damage was assessed after 
24 hours. Neurons were washed 3 times in PBS and homogenised in extraction buffer containing mixed 
protease and phosphatase inhibitors (as above) at 106 cells/ml. All experiments were performed in 
accordance with European regulations (European Community Council Directive, 1986, 56/609/EEC) and 
approved by the local authority veterinary service/ethical committee. 
Western Blotting - Samples were mixed with Laemmli buffer containing β-mercaptoethanol, heated to 
95oC for 5 minutes and proteins were separated by electrophoresis on 15% polyacrylamide gels. Proteins 
were transferred onto a Hybond-P polyvinylidene fluoride membrane by semi-dry blotting. Membranes 
were blocked using 10% milk powder; synapsin-1 was detected with goat polyclonal (Santa Crux Biotech), 
synaptophysin with MAB368 (Abcam), CSP with rabbit polyclonal anti-CSP ((sc-33154) Santa Cruz), 
vesicle-associated membrane protein (VAMP)-1 with mAb 4H302 (Abcam), rabbit polyclonal antibodies 
to caveolin (Upstate), platelet activating factor (PAF) receptor with rabbit polyclonal anti-PAF receptor 
(Cayman chemicals), APP with rabbit polyclonal anti-APP (Sigma) and PrPC by mAb 4F2 (Jaques Grassi 
[20]). These were visualised using a combination of biotinylated anti-mouse/goat/rat/rabbit IgG (Sigma), 
extravidin-peroxidase and enhanced chemiluminescence.   
Synaptophysin ELISA - Maxisorb immunoplates (Nunc) were coated with an anti-synaptophysin mouse 
mAb (MAB368 - Millipore) and bound synaptophysin was detected using rabbit polyclonal anti-
synaptophysin (Abcam) followed by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 1 
mg/ml 4-nitrophenol phosphate solution (Sigma). Absorbance was measured on a microplate reader at 405 
nm. Samples were expressed as “units synaptophysin” where 100 units were defined as the amount of 
synaptophysin in 106 control neurons. 
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CSP ELISA – Maxisorb immunoplates were coated with an anti-CSP mAb (Santa Cruz) and blocked with 
5% milk powder. Samples were added and bound CSP was detected using rabbit polyclonal anti-CSP (Santa 
Cruz) followed by a biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 1 mg/ml 4-
nitrophenol phosphate solution. Absorbance was measured at 405 nm. Samples were expressed as “units 
CSP” where 100 units were defined as the amount of CSP in 106 control neurons.  
Isolation of PrPC - PrPC and the control Thy-1 protein were isolated from murine GT1 neuronal cell 
membranes using a combination of immunoaffinity columns, size exclusion chromatography (Superdex) 
and reverse-phase chromatography on C18 columns (Waters) as described [21]. N-linked glycans were 
removed from PrPC by digestion with 2 units/ml endoglycosidase F (PNGase) (Sigma), monoacylated PrPC 
by digestion with 100 units/ml bee venom phospholipase A2 (PLA2) (Sigma) and desialylated PrPC by 
digestion with 0.2 units/ml neuraminidase (Clostridium perfringens - Sigma) for 2 hours at 37oC [21]. 
Digested PrPC preparations were purified using reverse phase chromatography (C18 columns); PrP positive 
fractions were pooled, desalted and lyophilised. For tissue culture studies PrP-containing fractions were 
solubilised in culture medium by sonication prior to further use.  
 
PrP ELISA - The amount of PrP in samples was measured by ELISA as described [21]. Briefly, maxisorb 
immunoplates were coated with mAb ICSM18 (gift Dr M Tayebi, Royal Veterinary College) and blocked 
with 5% milk powder. Samples were applied and detected with biotinylated mAb ICSM35 (gift Dr M 
Tayebi), followed by extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl phosphate solution. 
Absorbance was measured at 405 nm and the concentrations of PrP in samples were calculated by reference 
to serial dilutions of recombinant murine PrP (Prionics).  
 
Isolation of GPIs - Purified proteins were digested with 100 µg/ml proteinase K, at 37oC for 24 hours, 
resulting in GPIs attached to the terminal amino acid. The released GPIs were extracted with water-
saturated butanol, washed with water 5 times and loaded onto C18 columns. GPIs were eluted under a 
gradient of propanol and water. The presence of GPIs was detected by ELISA as described [21]. Maxisorb 
immunoplates were coated with 0.5 µg/ml concanavalin A (binds mannose) and blocked with 5% milk 
powder in PBS-tween. Samples were added and any bound GPI was detected by the addition of the 
phosphatidylinositol-reactive mAb 5AB3-11, followed by a biotinylated anti-mouse Ig (Sigma), extravidin-
alkaline phosphatase and 1mg/ml 4-nitrophenyl phosphate solution. Absorbance was measured on a 
microplate reader at 405 nm. For some experiments GPIs derived from PrPC were digested with 100 
units/ml bee venom PLA2 (monoacylated GPI) or 0.2 units/ml neuraminidase (desialylated GPI) for 2 hours 
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at 37oC. The modified GPIs were isolated on C18 columns as above. GPIs were dissolved in ethanol at 2 
µM (stock solutions) and diluted in tissue culture medium for bioassays.  
 
Analysis of GPIs - The presence of phosphatidylinositol in GPI anchors was identified using mAb (5AB3-
11) and specific glycans were detected with biotinylated lectins. Isolated GPIs were bound to nitrocellulose 
membranes by dot blot and blocked with 5% milk powder. Samples were incubated with mAb 5AB3-11, 
biotinylated Sambucus nigra agglutinin (SNA) (detects terminal sialic acid residues bound α-2,6 or α-2,3 
to galactose), biotinylated concanavalin A (detects mannose) or biotinylated Ricinus Communis Agglutinin 
I (RCA-I) (detects terminal galactose) (Vector Labs). Bound lectins were visualised using extravidin 
peroxidase and enhanced chemiluminescence. The mAb was visualised by incubation with a horseradish 
peroxidase conjugated anti-murine-Ig and chemiluminescence. GPIs were separated by high performance 
thin layer chromatography (HPTLC) on silica gel 60 plates using a mixture of chloroform/methanol/water 
(10/10/3 v/v/v). Plates were soaked in 0.1 % poly isobutyl methacrylate in hexane, dried, and blocked with 
5% milk powder. GPIs were detected with a mAb that binds to phosphatidylinositol as described [22].  
Brain extracts – Soluble extracts were prepared from brain tissue from patients with a clinical, and 
pathologically-confirmed, diagnosis of Alzheimer’s disease as described [12]. Briefly, brain tissue, stored 
at -80oC was thawed, cut into pieces of approximately 100 mg and added to 2 ml tubes containing lysing 
matrix D beads (Q-Bio). Ice cold 20 mM Tris, pH 7.4 containing 150 mM NaCl was added so that there 
was the equivalent of 100 mg brain tissue/ml. The tubes were shaken for 10 minutes (Disruptor genie, 
Scientific Instruments). This process was performed 3 times before tubes were centrifuged at 16,000 x g 
for 10 minutes to remove particulate matter. Soluble material was prepared by passage through a 50 kDa 
filter (Sartorius) (16,000 x g for 30 minutes to remove proteolytic enzymes, membrane-bound and plaque 
Aβ. The soluble material was then desalted (3 kDa filter (Sartorius)) to eliminate bioactive small molecules 
and drugs and the retained material collected (preparation contains peptides with molecular weights 
between 3 and 50 kDa) and stored at -80oC.  
APP ELISA – Maxisorb immunoplates were coated with mouse mAb anti-APP (Clone 1G6) Biolegend (epitope 
573-596)) and blocked with 5% milk powder in PBS-tween and samples were applied for 1 hour. Bound APP 
was detected using rabbit polyclonal antibodies against the N-terminal of APP (amino acids 40 to 60 - Sigma) followed 
by anti-rabbit IgG conjugated to alkaline phosphatase followed by 1 mg/ml 4-nitrophenol phosphate solution and 
optical density was read in a spectrophotometer at 405 nm. Results were calculated by comparison to serial 
dilutions of cell extracts from control cells. 
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Sample preparation – To detach Aβ42 from membrane components that block specific epitopes samples 
(300 µl) were mixed with 700 µl of propan-2-ol and sonicated. Proteins were precipitated by adding 250 
µls 100%w/v trichloroacetic acid, incubating on ice for 30 mins and centrifugation (16,000 x g for 10 mins 
at 4oC). The pellet was washed twice with ice cold acetone, dried, suspended in a buffer containing 150 
mM NaCl, 10 mM Tris-HCl, pH 7.4, 10 mM EDTA and 0.2% SDS and sonicated. 
 
Aβ42 ELISA –Nunc Maxisorb immunoplates were coated with mAb 4G8 (epitope 17-24) (Covance) in 
carbonate buffer overnight. Plates were blocked with 5% milk powder in PBS-tween and samples were 
applied. The detection antibody was an Aβ42 selective rabbit mAb BA3-9 (Covance) followed by 
biotinylated anti-rabbit IgG and extravidin alkaline phosphatase (Sigma). Total Aβ was visualised by 
addition of 1 ng/ml 4-nitrophenol phosphate solution and optical density was read in a spectrophotometer 
at 405 nm. 
 
Aβ40 ELISA - Maxisorb immunoplates were coated with mAb 4G8 (epitope 17-24) and blocked with 5% 
milk powder in PBS-tween. Samples were applied and Aβ40 was detected with rabbit polyclonal PC-149 
(Merck) followed by biotinylated anti-rabbit IgG and extravidin alkaline phosphatase. Total Aβ was 
visualised by addition of 1 ng/ml 4-nitrophenol phosphate and optical density was read in a 
spectrophotometer at 405 nm. 
Statistical Analysis - Comparison of treatment effects was carried out using Student’s paired t-tests. Error 
values are standard deviation (SD) and significance was determined where P<0.01. Bivariate analysis using 
Pearson’s coefficient (IBM SPSS statistics 20) were used to examine correlations between data sets. 
Results 
 
7PA2 cells release toxic Aβ – In support of the hypothesis that Aβ caused synapse damage, the CM from 
7PA2 cells caused dose-dependent reductions in synapsin-1, VAMP-1, CSP and synaptophysin from 
cultured neurons indicative of synapse damage (Figure 1A). The addition of 100 μg/ml 7PA2-CM did not 
reduce neuronal viability as measured by thiazolyl blue tetrazolium ((101% cell survival ± 6 compared with 
100% ± 5, n=9, P=0.6) indicating that synapse degeneration occurred in the absence of any significant 
neuronal death. Whereas 7PA2-CM caused dose-dependent reductions in both synaptophysin (Figure 1B) 
and CSP (Figure 1C), the addition of Aβ-depleted CM did not, indicating that Aβ was the synaptotoxic 
element. Immunoprecipitation studies demonstrated that the toxic entity in these CM was Aβ. 
Immunodepletion with mAb G48 reduced the concentrations of both Aβ42 (0.04 nM Aβ42 ± 0.04 compared 
with 2.21 nM ± 0.3, n=9, P<0.01) and Aβ40 (0.57 nM Aβ40 ± 0.28 nM compared with 7.42 nM Aβ40 ± 0.6 
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nM Aβ40, n=9, P=0.38). Mock-depletions with a control IgG mAb did not significantly affect the 
concentration of either Aβ40 (6.95 nm Aβ40 ± 0.81 compared with 7.42 nM Aβ40 ± 0.6, n=9, P=0.2) or Aβ42 
(2.03 nM Aβ42 ± 0.21 compared with 2.21 Aβ42 ± 0.3 nM, n=9, P=0.21). Not all forms of Aβ have equal 
biological significance, as toxicity is dependent upon the state of Aβ. To determine whether 7PA2-CM 
contained Aβ similar to the toxic Aβ in the brains of Alzheimer’s patients it was compared to that of soluble 
brain extracts. 7PA2-CM and brain extracts containing similar concentrations of Aβ42 caused similar dose-
dependent reductions in synaptophysin (Figure 1D) and CSP (Figure 1E). 
 
PrPC reduced the release of toxic Aβ from 7PA2 cells – Since PrPC had been reported to inhibit the 
production of Aβ42 [15] the effects of PrPC on 7PA2 cells were studied. The viability of 7PA2 cells, as 
measured by thiazolyl blue tetrazolium, was not significantly affected by 10 nM PrPC (102% cell survival 
± 6 compared with 100% ± 5, n=6, P=0.37). CM from 7PA2 cells treated with 10 nM PrPC did not cause 
synapse damage, as measured by the loss of synaptophysin (Figure 2A) from cultured neurons. 10 nM PrPC 
was used in these assays as this is the PrPC concentration in neurons [23]. The effects of PrPC were dose-
dependent. CM from cells with recombinant PrP (PrP protein lacking any post-translational modifications) 
had similar effects to CM from control cells indicating that the inhibitory effect of PrPC was due to a post-
translational modification. The effects of N-linked glycans PrPC upon the production of toxic Aβ were 
examined; CM from 7PA2 cells treated with PrPC from which N-linked glycans had been removed did not 
cause synapse damage. There were no significant differences between PrPC and PrPC lacking N-linked 
glycans upon the suppression of toxic Aβ production as measured by loss of synaptophysin (Figure 2B).  
 
PrPC-mediated suppression of toxic Aβ release is dependent upon its GPI - PrPC is connected to cell 
membranes by a GPI anchor [16]. The role of the GPI in PrPC-mediated suppression of toxic Aβ was 
examined using monoacylated PrPC, a form of PrPC differing from PrPC only in the lack of an acyl chain in 
its GPI anchor [24]. Following the addition of 10 nM PrPC preparations similar amounts of PrPC and 
monoacylated PrPC were found in 7PA2 cells (9.3 nM ± 0.6 compared with 9.5 nM ± 0.5, P=0.74, n=9). In 
addition the viability of 7PA2 cells as measured by thiazolyl blue tetrazolium was not significantly affected 
by 10 nM monoacylated PrPC (101% cell survival ± 6 compared with 100% ± 5, n=6, P=0.75). CM from 
cells treated with 10 nM monoacylated PrPC caused a reduction in synaptophysin similar to CM from 
untreated cells demonstrating that the inhibitory effect of PrPC on toxic Aβ production was GPI-dependent 
(Figure 2C). The CM from 7PA2 cells treated with Thy-1, another GPI-anchored protein, caused synapse 
damage, as measured by the loss of synaptophysin, similar to CM from control cells (Figure 2C) indicating 
that not all GPI-anchored proteins had this suppressive affect. Since the toxicity of 7PA2-CM is Aβ-
dependent it was surprising to see that treatment with 10 nM PrPC had only a small effect on the 
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concentrations of Aβ42 (2.05 nM ± 0.22 compared with 2.45 nM ± 0.38, n=9, P=0.02) or Aβ40 (6.94 nM ± 
1.04 compared with 7.28 nM ± 0.72, n=9, P=0.24) in CM.   
 
PrPC reduced the release of Aβ oligomers – Reports that Aβ monomers are not toxic [25, 26] suggested 
that the toxicity of 7PA2-CM was relative to the concentrations of Aβ oligomers rather than the total Aβ. 
Immunoblots showed that 7PA2-CM contained monomers, dimers and trimers (Figure 3A, Lane 1) while 
7PA2-CM retained by a 10 kDa filter was depleted of monomers but contained dimers and trimers (Figure 
3A, Lane 2). Treatment with PrPC, but not monoacylated PrPC, caused a dose-dependent reduction in Aβ42 
oligomers (Figure 3B). Treatment with 10 nM PrPC also reduced the concentrations of Aβ40 oligomers from 
0.41 nM ± 0.16 to 0.2 nM ± 0.14, n=9, P=0.03 whereas 10 nM monoacylated PrPC had no significant effect 
(0.47 nM ± 0.11 compared with 0.41 ± 0.16, n=9, P=0.4). There was a significant inverse correlation 
between the concentrations Aβ42 oligomers in CM from cells treated with PrPC (1.25  to 10 nM) and amounts 
of synaptophysin in neurons incubated with these CM, Pearson’s coefficient= -0.91, P<0.01 (Figure 3C). 
 
Immunoblots showed that 7PA2-CM that passed through a 10 kDa filter contained only Aβ monomers 
(Figure 4A, Lane 2).  Treatment with PrPC, but not monoacylated PrPC caused a dose-dependent increase 
in the concentrations of Aβ42 monomers in CM (Figure 4B). Treatment with 10 nM PrPC did not 
significantly alter the concentrations of Aβ40 monomers (7.1 nM Aβ40 ± 0.62 compared with 6.6 nM ± 0.58, 
n=9, P=0.07). A significant inverse correlation between the concentrations of Aβ42 oligomers and Aβ42 
monomers in CM from 7PA2 cells incubated with PrPC (1.25 to 10 nM), Pearson’s coefficient= -0.75, 
P<0.01 was observed (Figure 4C).  
 
GPIs reduced the release of toxic Aβ – Since these results indicated that the GPI attached to PrPC had a 
role in suppressing Aβ42 oligomer production, we hypothesised that GPIs alone could alter Aβ production. 
Analysis of GPIs isolated from PrPC and Thy-1 by HPTLC (Figure 5A) and reverse phase chromatography 
on C18 columns (Figure 5B) showed that they had different properties. Whereas CM from 7PA2 cells 
treated with 10 nM GPIs derived from PrPC did not cause synapse damage (did not affect the synaptophysin 
(Figure 5C) or CSP (Figure 5D) content of neurons), the CM from 7PA2 cells treated with 10 nM GPIs 
isolated from Thy-1 caused extensive loss of synaptophysin and CSP. The effects of PrPC-derived GPIs on 
the production of toxic Aβ were dose-dependent (Figure 5E). These results showed that the GPI-induced 
suppression of toxic Aβ production was structure dependent. 
 
CM from cells treated with PrPC-derived GPIs, but not Thy-1-derived GPIs, showed a dose-dependent 
reduction in Aβ42 oligomers (Figure 6A) and increase in Aβ42 monomers (Figure 6B). There was a 
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significant inverse correlation between concentrations of Aβ42 oligomers and Aβ42 monomers in CM from 
7PA2 cells incubated with PrPC-derived GPIs (1.25 to 10 nM), Pearson’s coefficient= 0.87, P<0.01 (Figure 
6C). The loss of Aβ oligomers and corresponding increase in Aβ monomers suggested that the GPIs may 
interact directly with Aβ oligomers causing them to dissociate into monomers. When Aβ preparations 
(containing 10 nM Aβ42) and incubated with 10 nM GPIs at 37oC for 3 days were analysed by 
electrophoresis and immunoblot there was no difference in the proportion of oligomers and monomers 
(Figure 6D). In addition, monomeric forms of Aβ42 were not found in Aβ oligomer preparations incubated 
with GPIs; indicating that GPIs did not cause the dissociation of Aβ oligomers.  
 
Sialylated GPIs reduced the release of toxic Aβ42 – The composition of GPIs derived from PrPC are 
unusual in that they contain sialic acid [16] and (Figure 7A), a rare modification of mammalian GPIs. To 
examine the structure-function relationship in more detail the GPIs derived from PrPC were digested to 
create desialylated GPIs and monoacylated GPIs. GPIs, desialylated GPIs and monoacylated GPIs were 
visualised by HPTLC (Figure 7B) and isolated by reverse phase chromatography on C18 columns (Figure 
7C). In dot blots all GPIs reacted with mAb 5AB3-11 (reactive with phosphatidylinositol) and concanavalin 
A (mannose). SNA (detects terminal sialic acid residues bound α-2,6 or α-2,3 to galactose) bound to GPIs 
and monoacylated GPIs but not to desialylated GPIs (Figure 7D). Conversely, RCA-1 (detects terminal 
galactose) only bound to desialylated GPIs. 
 
The CM from 7PA2 cells treated with 10 nM GPI preparations was added to cultured neurons. CM from 
7PA2 cells treated with control medium, 10 nM monoacylated GPIs or 10 nM desialylated GPIs reduced 
the amounts of synaptophysin in neurons, whereas CM from cells treated with GPIs did not (Figure 8A). 
The effects of PrPC-derived GPIs were dose-dependent (Figure 8B). Treatment of 7PA2 cells with 10 nM 
GPIs, but not monoacylated GPIs or desialylated GPIs (10 nM), reduced the concentrations of Aβ42 
oligomers (Figure 8C) and increased the concentrations of Aβ42 monomers in CM (Figure 8D).  
 
GPIs increased the release of neuroprotective Aβ – To determine if Aβ monomers have a protective role 
the CM from GPI-treated 7PA2 cells were mixed with brain extract containing 2 nM Aβ42 and incubated 
with neurons. The brain extract caused a reduction in synaptophysin (Figure 9A) and CSP (Figure 9B). The 
presence of CM from GPI-treated 7PA2 cells protected neurons against the brain extract (Aβ)-induced 
synapse damage. It was important to determine whether the protective effect of CM from treated 7PA2 cells 
was mediated by Aβ. Therefore, brain extracts were incubated with CM from GPI-treated cells after Aβ 
had been removed by immunoprecipitation and added to neurons. Removal of Aβ removed the protective 
effects of CM from GPI-treated cells (Figures 9A & B). Next, Aβ monomers were isolated from the CM of 
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GPI-treated cells. Aβ monomers blocked the brain extract-induced reductions in synaptophysin (Figure 9C) 
and CSP (Figure 9D). The protective effects of monomer preparations derived from GPI-treated 7PA2 cells 
were compared to that of monomers prepared from brain extracts.  Monomer preparations derived from 
7PA2-CM and brain extract had similar activity when based on their Aβ42 content (Figure 9E). The 
protective effect of these monomer preparations was stimulus specific; there were no significant differences 
in either synaptophysin (31 units ± 7 compared with 34 ± 10, n=9, P=0.37) or CSP (54 units ± 6 compared 
with 50 ± 13, n=9, P=0.4) content of neurons incubated with 10 nM prostaglandin E2 ± monomer 
preparations containing 10 nM Aβ42. 
 
PrPC and GPIs reduced cell-associated Aβ - The possibility that PrPC or GPIs affected the release, rather 
than the production of Aβ was examined by measuring Aβ in cell extracts from treated 7PA2 cells. The 
concentrations of Aβ42 in 7PA2 cells was significantly reduced by treatment with 10 nM PrPC (6.7 nM Aβ42 
± 1.7 compared with 12.15 nM ± 1.93, n=12, P<0.01) or with 10 nM GPIs derived from PrPC (5.67 nM 
Aβ42 ± 1.34 compared with 12.15 nM ± 1.93, n=12, P<0.01).  The concentrations of Aβ42 were not 
significantly affected by treatment with 10 nM monoacylated PrPC (12.55 nM Aβ42 ± 2.1 compared with 
12.15 nM ± 1.93, n=12, P=0.74) or 10 nM desialylated GPIs (12.76 nM Aβ42 ± 2.16 compared with 12.15 
nM ± 1.93, n=12, P=0.42). 
GPIs altered the distribution of APP – Further studies examined the effects of GPIs upon APP. Treatment 
with 10 nM GPI did not significantly alter concentrations of APP within cells (97 units ± 3.4 compared 
with 100 units ± 2.8, n=6, P=0.14). The processing of APP to toxic Aβ peptides is thought to occur within 
membrane micro-domains called lipid rafts and in control cells approximately 25% of cellular APP was 
found within DRMs (lipid rafts). Treatment with 10 nM GPI, but not 10 nM desialylated GPI, reduced the 
amounts of APP found within DRMs in a dose-dependent manner (Figure 10A). Treatment of 7PA2 cells 
with 10 nM GPI did not affect the amounts of other raft-associated proteins including caveolin and the PAF 
receptor in DRMs (Figure 10B). In cells treated with GPIs (1.25 to 10 nM) there was a significant 
correlation between the amounts of APP found in lipid rafts and the concentrations of Aβ42 oligomers found 
in CM (Figure 10C). There was also a significant inverse correlation between the amounts of APP found in 
lipid rafts and the concentrations of Aβ42 monomers found in CM (Figure 10D). 
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Discussion 
 
There are 2 key findings from this study; firstly that the release of toxic Aβ from 7PA2 cells is controlled 
by a pathway sensitive to the presence of PrPC. More specifically that it was the sialic acid contained within 
the GPI anchor attached to PrPC that affected Aβ production. Secondly, we report that the GPI-induced 
changes involved both a reduction in toxic Aβ oligomers and an increase in neuroprotective Aβ monomers.  
 
This study concentrated on the biologically active forms of Aβ released by 7PA2 cells by measuring their 
effects upon synapses (based on reports that synapse damage, as measured by the loss of synaptic proteins, 
is a good correlate of dementia in AD [7, 8, 27, 28]). The finding that synapse damage caused by CM from 
7PA2 cells was comparable to that caused by soluble Alzheimer’s brain extracts (with regard to their Aβ42 
content) implied that 7PA2 cells release toxic Aβ oligomers that are similar to those found within the brains 
of AD patients. The major observation was that the CM collected from 7PA2 cells treated with PrPC did 
not damage synapses. However, in contrast to the initial report that expression of PrPC reduced Aβ 
production in transfected human neuroblastoma cells [15] we found that PrPC had only minor effects on the 
concentrations of Aβ40 and Aβ42. It should be noted that the 2 systems are very different with regard to cell 
types and the amounts of PrPC expressed. 
 
Observations that recombinant PrP, which does not contain post-translational modifications such as GPIs 
and N-linked glycans, did not affect the production of toxic Aβ demonstrated that the protein alone was not 
responsible for suppression of Aβ production and led us to examine the effects of post-translational 
modifications of PrPC. We concluded that N-linked glycans were not necessary for the suppression of toxic 
Aβ production as their removal from PrPC also inhibited the production of toxic Aβ. In contrast, 
monoacylated PrPC, a form of PrPC that differed only in the composition of its GPI anchor, did not suppress 
toxic Aβ release indicating a role for the GPI anchor in regulating Aβ production. The observation that 
isolated GPIs were capable of suppressing toxic Aβ release and altering the ratio of Aβ monomers to Aβ 
oligomers showed that the GPI alone affected Aβ production and that the GPI was not simply a contributory 
factor to protein interactions mediated by PrPC. The structure of the GPI was important as GPIs isolated 
from Thy-1, or GPIs derived from PrPC that had been modified (monoacylated or desialylated GPIs) did not 
affect the release of toxic Aβ.   
 
The observation that PrPC reduced the toxicity of CM from 7PA2 cells without causing major changes in 
the concentrations of Aβ40 and Aβ42 indicated that it affected the forms of Aβ produced. Thus, the presence 
of PrPC has 2 major effects; it reduced the concentrations of Aβ42 oligomers, responsible for synapse 
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damage, and it increased the release of Aβ42 monomers. Immunodepletion and filtration studies showed 
that the protective effect was mediated by Aβ monomers, an observation consistent with a prior report [29]. 
These results are consistent with the hypothesis that it is the ratio of Aβ monomers to Aβ oligomers that is 
critical factor in determining the toxicity of CM and explained the observation that CM from cells treated 
with GPIs (which increased concentrations of Aβ42 monomers) blocked synapse damage caused by soluble 
Aβ oligomers. The protective effects of Aβ monomers were stimulus specific; they did not affect synapse 
damage induced by prostaglandin E2 indicating a selective rather than a universal action.  
 
The GPIs did not have a direct effect on Aβ42 oligomers (did not cause the dissociation of oligomers into 
monomers); rather the effects of GPIs were upon the production of oligomers and monomers. Currently we 
can only speculate how specific sialylated GPIs might alter the production of toxic Aβ. Observations that 
GPIs help solubilise cholesterol and that GPI-anchored proteins triggered the formation of lipid rafts [30, 
31] implicate GPI-anchored proteins as regulators of lipid raft structure and function. The processing of 
APP by β- and γ-secretases to form Aβ is affected by the composition of cell membranes; more specifically 
the form and function of lipid rafts [32, 33]. Notably, PrPC-mediated inhibition of β-secretase was dependent 
upon lipid rafts [15] and in this study monoacylated PrPC and monoacylated GPIs, which were not found 
within lipid rafts [24], did not affect Aβ production, observations that support the idea that GPIs affected 
lipid raft function.  
 
Not all GPIs suppressed the production of toxic Aβ; GPIs derived from Thy-1, monoacylated PrPC or 
desialylated PrPC had an inhibitory effect. The glycan structure of the GPI anchor mediates protein 
association with specific rafts [34] and affects the function of those rafts [35]. The composition of lipid 
rafts surrounding GPIs are dependent upon multiple interactions between the glycans and membrane lipids 
[36, 37] and the removal of sialic acid from the GPI of PrPC changed the properties of the surrounding lipid 
raft; it allowed increased concentrations of gangliosides and cholesterol [22]. Although APP metabolism to 
toxic Aβ is thought to occur within lipid rafts [38] cells contain multiple, heterogeneous lipid rafts each 
with different composition and functions [39]. We hypothesised that GPIs derived from PrPC are targeted 
to lipid rafts involved in the metabolism of APP to toxic Aβ. Lipid rafts are enriched with signalling 
molecules and act as domains in which the GPI anchors attached to PrPC interact with cell signalling 
pathways [40]. The GPIs attached to PrPC activate cPLA2 [22] an enzyme that affects APP processing [41]. 
As this enzyme is essential for the maintenance of the endoplasmic reticulum-trans golgi network [42], a 
pathway reported to regulate APP metabolism [43], then inhibition of cPLA2 may affect the intracellular 
trafficking of APP and hence its metabolism to toxic Aβ.   
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APP and many of the enzymes involved in the generation of Aβ are found in lipid rafts [44-46] and in 
control 7PA2 cells approximately 25% of APP was found within lipid rafts. The observation that GPIs 
reduced the amounts of APP within lipid rafts is consistent with reports that GPIs sequester cholesterol and 
consequently affect lipid raft composition and function [31, 47]. The finding that there was a significant 
positive correlation between the concentrations of Aβ42 oligomers and the amounts of APP in lipid rafts of 
Aβ42 monomers suggests that membrane targeting of APP is a key factor in production of Aβ oligomers. 
The protein cargos of the cell membrane traffic via different pathways to those within lipid rafts [48] and 
APP in lipid rafts may be targeted to different cell compartments (and consequently interacts with a different 
range of enzymes) than APP found in the cell membrane.  
 
In summary this study demonstrated that the release of toxic Aβ by 7PA2 cells is sensitive to the presence 
of PrPC and more specifically, its sialylated GPI anchor. Critically, sialylated GPIs derived from PrPC 
increased the release of neuroprotective Aβ monomers and reduced the release of toxic Aβ oligomers.  
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Soluble Aβ caused synapse damage in neurons - (A) Immunoblots showing the amounts of 
synapsin-1, VAMP-1, CSP, synaptophysin and caveolin in neurons incubated with 7PA2-CM as shown. 
The amounts of synaptophysin (B) and CSP (C) in neurons incubated with CHO-CM (■) or 7PA2-CM, Aβ-
depleted 7PA2-CM or mock-depleted 7PA2-CM (□). Values are means ± SD from triplicate experiments 
performed 3 times, n=9. The amounts of synaptophysin (D) and CSP (E) in neurons incubated with 7PA2-
CM (○) or soluble brain extract (●) containing Aβ42 as shown. Values are means ± SD from triplicate 
experiments performed 3 times, n=9.  
 
 
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. PrPC reduced the release of toxic Aβ – (A) The amounts of synaptophysin in neurons incubated 
with CM from 7PA2 cells treated with concentrations of PrPC (■) or recombinant PrP (vertical striped bars) 
as shown. Values are means ± SD from triplicate experiments performed 3 times, n=9. *=amounts of 
synaptophysin significantly greater than in neurons incubated with CM from untreated cells, P<0.05. (B) 
The amounts of synaptophysin in neurons incubated with CM from 7PA2 cells treated with concentrations 
of PrPC (■) or PrPC without N-linked glycans (striped bars) as shown. Values are means ± SD from triplicate 
experiments performed 3 times, n=9. (C) The amounts of synaptophysin in neurons incubated with CM 
from 7PA2 cells treated with concentrations of PrPC (■), Thy-1 (hatched bars) or monoacylated PrPC 
(horizontal striped bars) as shown. Values are means ± SD from triplicate experiments performed 3 times, 
n=9. *=amounts of synaptophysin significantly greater than in neurons incubated with CM from untreated 
cells, P<0.05.  
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Figure 3. PrPC reduced the release of Aβ oligomers (A) Immunoblot showing forms of Aβ (monomers 
(M), dimers (D) and trimers (T)) in 7PA2-CM (1) and 7PA2-CM retained by a 10 kDa filter (2). (B) The 
concentrations of Aβ42 oligomers in CM from 7PA2 cells treated with PrPC (■) or monoacylated PrPC (□) 
as shown. Values are means ± SD from triplicate experiments performed 3 times, n=9. *= concentrations 
of Aβ significantly less than in control 7PA2-CM, P<0.05 (C) There was a significant inverse correlation 
between the concentrations of Aβ42 oligomers in CM from cells treated with PrPC (10 to 1.25 nM) and the 
amounts of synaptophysin in neurons incubated with these CM, Pearson’s coefficient= -0.91, P<0.01. 
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Figure 4. PrPC increased the release of Aβ monomers – (A) Immunoblot showing forms of Aβ  
(monomers (M), dimers (D) and trimers (T)) in 7PA2-CM (1) and in 7PA2-CM that passed through a 10 
kDa filter (2). (B) The concentrations of Aβ42 monomers in CM from 7PA2 cells treated with PrPC (■) or 
monoacylated PrPC (□) as shown. Values are means ± SD from triplicate experiments performed 3 times, 
n=9. *=concentration of Aβ42 monomers significantly higher than in control 7PA2-CM, P<0.05. (C) There 
was a significant inverse correlation between concentrations of Aβ42 oligomers and Aβ42 monomers in CM 
from 7PA2 cells incubated with PrPC (10 to 1.25 nM), Pearson’s coefficient= -0.75, P<0.01.  
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Figure 5. GPIs reduced the release of toxic Aβ – (A) Blot showing GPIs derived from PrPC (1) or Thy-1 
(2) separated by HPTLC. (B) The amounts of GPIs derived from PrPC (●) or Thy-1 () in fractions eluted 
from a C18 column. Values are means of duplicates. The amounts of synaptophysin (C) and CSP (D) in 
neurons incubated with CM from 7PA2 cells treated with 10 nM GPIs derived from PrPC (●) or from Thy-
1 ().Values are means ± SD from triplicate experiments performed 3 times, n=9. (E) The amounts of 
synaptophysin in neurons incubated with CM from 7PA2 cells treated with GPIs derived from PrPC (■) or 
Thy-1 (hatched bars) as shown. Values are means ± SD from triplicate experiments performed 3 times, n=9. 
*=amounts of synaptophysin significantly greater than in neurons incubated with 7PA2-CM, P<0.05.  
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Figure 6. GPIs increased the release of Aβ monomers - The concentrations of Aβ42 oligomers (A) and 
Aβ42 monomers (B) in CM from 7PA2 cells treated with GPIs derived from PrPC (■) or Thy-1 (hatched 
bars) as shown. Values are means ± SD from triplicate experiments performed 3 times, n=9. 
*=concentrations of Aβ42 oligomers/monomers significantly different from those in CM from control cells, 
P<0.05. (C) There was a significant inverse correlation between concentrations of Aβ42 oligomers and Aβ42 
monomers in CM from 7PA2 cells treated with PrPC-derived GPIs (10 to 1.25 nM), Pearson’s coefficient= 
0.87, P<0.01. (D) Immunoblot showing forms of Aβ (monomers (M), dimers (D) and trimers (T)) in 7PA2-
CM incubated at 37oC for 3 days with control medium (1) or 10 nM GPIs (2). 
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Figure 7. Analysis of GPIs - (A) Schematic showing the putative GPI derived from PrPC. (B) Blot showing 
GPIs (1), desialylated GPIs (2) and monoacylated GPIs (3) separated by HPTLC. (C) The amounts of GPIs 
in fractions eluted from a C18 column loaded with GPIs derived from PrPC (●), monoacylated GPIs (□) and 
desialylated GPIs (■). Values are means of duplicates. (D) Dot blots showing the reactivity of mAb 5AB3-
11 (reactive with phosphatidylinositol), biotinylated concanavalin A (reacts with mannose), biotinylated 
SNA (reactive with terminal sialic acid) or biotinylated RCA-1 (reactive with terminal galactose) with GPIs 
derived from PrPC, monoacylated-GPIs and desialylated GPIs.  
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Figure 8. GPI-mediated suppression of toxic Aβ release is dependent upon sialic acid -  (A) The 
amounts of synaptophysin in neurons incubated with CM from 7PA2 cells treated with control medium (□), 
10 nM GPIs (■), 10 nM monoacylated GPIs (striped bars) or 10 nM desialylated GPIs (hatched bars). 
Values are means ± SD from triplicate experiments performed 3 times, n=9. (B) The amounts of 
synaptophysin in neurons incubated with CM from 7PA2 cells treated with GPIs (●), monoacylated GPIs 
(□) or desialylated GPIs (■) as shown. Values are means ± SD from triplicate experiments performed 3 
times n=9.  The concentrations of Aβ42 oligomers (C) and Aβ42 monomers (D) in CM from 7PA2 cells 
treated with control medium (□), 10 nM GPIs (■) 10 nM monoacylated GPIs (striped bars) or 10 nM 
desialylated GPIs (hatched bars). Values are means ± SD from triplicate experiments performed 3 times, 
n=9.   
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Figure 9. GPI-treated 7PA2 cells release neuroprotective Aβ monomers - The amounts of 
synaptophysin (A) and CSP (B) in neurons incubated with brain extract containing 2 nM Aβ42 mixed with 
control medium (□), CM from 7PA2 cells treated with PrPC-derived GPIs (■) or the same CM depleted of 
Aβ (striped bar) or mock-depleted (hatched bar). Values are means ± SD from triplicate experiments 
performed 3 times, n=9.  The amounts of synaptophysin (C) and CSP (D) in neurons incubated with 1nM 
Aβ42 mixed with control medium (□), CM from 7PA2 cells treated with PrPC-derived GPIs (■), or 
monomers (striped bar) isolated from this CM. Values are means ± SD from triplicate experiments 
performed 3 times, n=9.  (E) The amounts of synaptophysin in neurons pre-treated with Aβ monomers 
derived from 7PA2-CM (●) or from brain extract (○) as shown and incubated with brain extract containing 
1 nM Aβ42. Values are means ± SD from triplicate experiments performed 4 times, n=12.   
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Figure 10 - GPIs reduced APP within lipid rafts – (A) The amounts of APP in DRMs (Rafts) in 7PA2 
cells treated with GPIs (●) or desialylated GPIs (□) as shown. Values are means ± SD from triplicate 
experiments performed 3 times, n=9.  (B) Immunoblots showing the amounts of APP, caveolin and PAF 
receptors in DRMs (rafts) from 7PA2 cells treated with control medium (1), 10 nM GPIs (2) or 10 nM 
desialylated GPIs (3).  (C) There was a significant correlation between the amounts of APP in lipid rafts 
(DRMs) and the concentrations of Aβ42 oligomers found in CM from 7PA2 cells treated with GPIs (1.25 to 
10 nM), Pearson’s coefficient =0.84, P<0.01. (D). There was a significant inverse correlation between the 
amounts of APP in lipid rafts (DRMs) and the concentrations of Aβ42 monomers found in CM from 7PA2 
cells treated with GPIs (1.25 to 10 nM), Pearson’s coefficient= -0.79, P<0.01. 
 
